Continue enoxaparin for duration of hospitalization, up to 8 days, if given before diagnostic angiography.80 82,96 (Level of Evidence: A) 3. Continue fondaparinux for duration of hospitalization, up to 8 days, if given before diagnostic angiography.83 (Level of Evidence: B) 4. Either discontinue bivalirudin or continue at a dose of 0.25 mg/kg per hour for up to 72 hours at the physician s discretion if given before diagnostic angiography.77,108,109 (Level of Evidence: B) 7. For UA/NSTEMI patients in whom a conservative strategy is selected and who do not undergo angiography or stress testing, the instructions noted below should be followed: modified (included ticagrelor; duration of antiplatelet therapy changed to up to 12 months ). a. Continue aspirin indefinitely.61,63,64 (Level of Evidence: A) b. Continue clopidogrel or ticagrelor* for up to 12 months.9,13,67,110 (Level of Evidence: B) c. Discontinue IV GP IIb/IIIa inhibitor if started previously.50,51 (Level of Evidence: A) d. Continue UFH for 48 hours66,79 (Level of Evidence: A) or administer enoxaparin80 82 (Level of Evidence: A) or fondaparinux83 (Level of Evidence: B) for the duration of hospitalization, up to 8 days, and then discontinue anticoagulant therapy. 8. For UA/NSTEMI patients in whom an initial conservative strategy is selected and in whom no subsequent features appear that would necessitate diagnostic angiography (recurrent symptoms/ischemia, heart failure, or serious arrhythmias), LVEF should be measured.55,111 114 (Level of Evidence: B) 2007 recommendation remains current. Class IIa 1. For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, it is reasonable to administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) if not started before diagnostic angiography, particularly for troponin-positive and/or other high-risk patients.55,58 (Level of Evidence: A) 2011 recommendation remains current. 2. 